The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.50
Bid: 21.00
Ask: 22.00
Change: -2.50 (-10.64%)
Spread: 1.00 (4.762%)
Open: 24.25
High: 21.00
Low: 21.00
Prev. Close: 23.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Company Announces Strengthening Sales

24 Oct 2011 07:00

RNS Number : 6687Q
Angle PLC
24 October 2011
 



For immediate release

24 October 2011

 

ANGLE plc

 

("ANGLE" or the "Company")

 

PORTFOLIO COMPANY GEOMERICS ANNOUNCES STRENGTHENING SALES

 

 

ANGLE plc, which focuses on the commercialisation of technology, is pleased to announce that its 33% owned portfolio company Geomerics, which specialises in computer games middleware, has made significant progress on a number of fronts.

 

Sales continue to grow at an encouraging rate. Geomerics' Enlighten technology is now being employed in 18 titles worldwide and is currently in evaluation and under consideration for many more. Among these titles are two of the most hotly anticipated games of 2011. Battlefield 3, from EA DICE, is released on 28th October. It is considered a challenger to Call of Duty's market dominance. The game has been backed by a $100m marketing campaign and has received high praise and multiple awards for the quality of its graphics, of which the lighting is driven by Geomerics' Enlighten engine. Battlefield 3 is followed by the release of Need for Speed: The Run on 18th November. This is the next game in one of the most successful franchises of all time and is built on the same Enlighten technology as Battlefield 3.

 

Geomerics is also delighted that it has secured its first deal inside Korea, which will see Enlighten used in multiple titles. This opens up a whole new market for Enlighten and, on the back of sales in Japan, demonstrates that Geomerics is on its way to establishing a strong base in the Asian market.

 

Geomerics' participation in Epic Games' prestigious Unreal Engine 3 Integrated Partners Programme continues to go well and is yielding a range of new sales opportunities.

 

Finally, Geomerics has been awarded new grant funding to research applications of its technology on mobile devices. Geomerics will receive €470,000 over the next three years as part of a €2.8 million EU-funded project researching the next generation of graphics technology for mobile platforms.

 

 

 

Chris Doran, Founder of Geomerics, commented:

"At Geomerics we have tracked the rise in performance of mobile platforms very closely. It is clear that they are fast approaching console performance, and at the high end will overtake this in 2012. We are very excited about the prospect of taking our console technology to mobile platforms, and to contributing to joint R&D on the future direction of graphics technology for mobile devices."

 

 

Andrew Newland, Chief Executive of ANGLE commented:

"We are very pleased with the Geomerics' continued strong progress and look forward to the positive market impact when Battlefield 3 launches at the end of this week."

 

 

 

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Matt Goode

 

0207 523 8325

Buchanan

Lisa Baderoon

 

0207 466 5000

Scott Harris

Stephen Scott, Harry Dee

 

0207 653 0030

 

 

About Geomerics www.geomerics.com

 

Geomerics is an innovation-led company developing cutting-edge graphics technology for the games industry. Based in Cambridge, UK, Geomerics has built a team that combines world-class management and games industry experience with some of the UK's leading researchers. Geomerics launched its groundbreaking Enlighten technology in 2009. Enlighten redefines how designers use and control lighting within a game.

 

Geomerics partners with many of the leading companies in the games industry and is currently working with developers around the world on AAA titles for release in 2011 and 2012. The first titles incorporating Enlighten include the highly anticipated 'Battlefield 3' and 'Need for Speed: The Run'.

 

For more details about Geomerics research into mobile platforms, visit www.lpgpu.org 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRBDGLBDBGBX
Date   Source Headline
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting
21st Oct 20226:15 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.